晶丰明源：9月8日召开董事会会议

Group 1 - The core point of the article is that Jingfeng Mingyuan (SH 688368) announced the convening of its third board meeting on September 8, 2025, to discuss the proposal to cancel certain unvested restricted stocks [1] - For the fiscal year 2024, Jingfeng Mingyuan's revenue composition is heavily weighted towards integrated circuits, accounting for 99.94%, while other businesses contribute only 0.06% [1] - As of the report date, Jingfeng Mingyuan has a market capitalization of 8.4 billion yuan [1] Group 2 - The article highlights a significant shift in the perception of Chinese data by multinational pharmaceutical companies, indicating a newfound trust in the data coming from China [1] - The narrative emphasizes the rapid growth and innovation in China's pharmaceutical sector over the past 14 years, as experienced by Chen Zhisheng [1]